Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Claude James is active.

Publication


Featured researches published by Claude James.


Biochemical Pharmacology | 1987

Paf binding sites: Characterization by [3H] 52770 RP, a pyrrolo [1,2-c] thiazole derivative, in rabbit platelets

Christine Robaut; Gabrielle Durand; Claude James; Daniel Lave; Pierre Sedivy; Anne Floch; Serge Mondot; Daniel Pacot; Icilio Cavero; Gérard Le Fur

52770 RP, the N-(3-chlorophenyl)-3-(3-pyridinyl)-1H,3H-pyrrolo[1,2-c]thiazole -7-carboxamide, displaces in a potent, specific and competitive manner [3H]PAF from its binding sites on rabbit platelets. Since 52770 RP is not structurally related to PAF and has low liposolubility with respect to PAF, it was selected as a potential radioligand for PAF receptor sites. [3H]52770 RP displayed high-affinity, specificity, as well as saturable and displaceable binding to a single class of recognition sites in intact platelets and crude platelet membranes. In these preparations, the values of binding parameters were, respectively, 8.5 and 7.6 nM for Kd, 0.2 pmol/5 X 10(7) platelets and 3.66 pmol/mg protein for Bmax and 0.96 and 0.91 for nH. Inasmuch as the (+)-52770 RP was 300-fold more potent than the (-)-isomer at displacing [3H]52770 RP in intact platelets, the studied binding site manifested stereospecific discrimination. A variety of pharmacological agents including pro- and anti-aggregant compounds did not exhibit affinity for [3H]52770 RP binding sites. In contrast, PAF, some of its active analogues and several recognized PAF antagonists (BN 52021, brotizolam, L-652,731, triazolam), displaced the [3H]52770 RP binding. Studies carried out using [3H]PAF demonstrated that 52770 RP was approximately 4- and 200-fold more potent than L-652,731 and BN 52021 respectively, as a PAF-receptor antagonist. In washed rabbit platelets, the rank order of potency (Ki) for several analogues of 52770 RP, to displace [3H]PAF from its binding sites, was highly correlated (r = 0.96) to their ability to antagonize [3H]52770 RP binding. In functional studies, 52770 RP antagonized not only the PAF-induced aggregation in washed rabbit platelets but also the hypotension evoked by PAF in the anesthetized rat. In this respect, it was 26 and 2 times more potent than L-652,731, respectively. In conclusion, [3H]52770 RP might represent a novel interesting tool for furthering our understanding of the role of PAF binding sites in pathophysiological processes.


Tetrahedron Letters | 1985

Une cycloaddition dipolaire-1,3 inattendue du chloro-2 acrylonitrile

Jean-Louis Fabre; Daniel Farge; Claude James; Daniel Lave

Abstract The 1,3-dipolar cycloaddition of 2-chloroacrylonitrile on N-(2-pyridinecarbonyl) proline 1a and thio analogue 1b affords unexpected bridged compounds 2 and 3, the reactivity of which versus H2S is described.


Journal of The Chemical Society-perkin Transactions 1 | 1989

Synthesis of RP 56142: a new immunoactive peptide

Jean Bouchaudon; Gilles Dutruc-Rosset; Daniel Farge; Claude James

RP 56142, a new immunoactive peptide was synthesized on large scale (ca. 500 g)viaL-2,6-diaminopimelic acid which was prepared by chemical or biochemical synthesis. The key derivative, N6-benzyloxycarbonyl-L-2,6-diaminopimelamic acid was synthesized by two methods. In the first, we used a copper chelate procedure. In the second, we selectively deblocked the amine at the α-position to the free carboxylic group by the N-carboxyanhydride method. Condensation of N6-benzyloxycarbonyl-L-2,6-diaminopimelamic acid and the appropriately protected lauroyl dipeptide and removal of the protecting groups afforded RP 56142.


Journal of Medicinal Chemistry | 1996

Betulinic Acid Derivatives: A New Class of Human Immunodeficiency Virus Type 1 Specific Inhibitors with a New Mode of Action

Michel Evers; Christèle Poujade; Francoise Soler; Yves Ribeill; Claude James; Yves Lelièvre; Jean-Christophe Gueguen; Daniel Reisdorf; Isabelle Morize; Rudi Pauwels; Erik De Clercq; Yvette Henin; Anne Bousseau; Jean-Francois Mayaux; and Jean-Bernard Le Pecq; Norbert Dereu


Archive | 1994

Lupane derivatives, their preparation and the pharmaceutical compositions which contain them

Romaine Bouboutou; Norbert Dereu; Michel Evers; Jean-Christophe Gueguen; Claude James; Christèle Poujade; Daniel Reisdorf; Yves Ribeill; Francoise Soler


Journal of Medicinal Chemistry | 1987

Synthesis and antisecretory and antiulcer activities of derivatives and analogues of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide.

Jean-Claude Aloup; Jean Bouchaudon; Daniel Farge; Claude James; Jean Deregnaucourt; Monique Hardy-Houis


Archive | 1989

Medicaments containing 2-benzothiazolamine derivatives, compounds and their preparation

Francois Audiau; Claude James


Archive | 1991

Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation

Francois Audiau; Claude James


Archive | 1987

1H,3H-pyrrolo[1,2-c]thiazole derivatives, their preparation and pharmaceutical compositions containing them

Jean-Louis Fabre; Claude James; Daniel Lave


Archive | 1984

Derivatives of 1H,3H-pyrrolo(1,2-c)thiazole, their preparation and pharmaceuticals containing them

Jean-Louis Fabre; Daniel Farge; Claude James; Daniel Lave

Collaboration


Dive into the Claude James's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge